PRTA

Business Context and Reporting Period

Company: Prothena Corporation plc (PRTA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Prothena is a late-stage clinical biotechnology company focused on protein dysregulation, targeting neurodegenerative and rare peripheral amyloid diseases. Key programs include prasinezumab (Parkinson's, partnered with Roche), BMS-986446 (Alzheimer's, partnered with BMS), and PRX019 (neurodegenerative, partnered with BMS). The company sold its ATTR amyloidosis business (coramitug) to Novo Nordisk in 2021.

Key Financial Metrics (Nine Months Ended Sept 30, 2025)

Material Changes vs. Prior Period

• Revenue Decline: Total revenue dropped 93% to $9.7 million from $133.0 million in the prior year period. The 2024 figure included $107.9 million from the PRX019 Global License Agreement and $25.0 million from expired material rights for the TDP-43 target. Current revenue is primarily from the partial performance of the PRX019 Phase 1 Clinical Trial Obligation.
• Restructuring Charges: The company incurred $33.1 million in restructuring costs in 2025 (none in 2024) following the discontinuation of the birtamimab program and a 63% workforce reduction announced in June 2025.
• Operating Expenses: Total operating expenses decreased 10% to $200.1 million, driven by a 30% reduction in R&D expenses due to program wind-downs (birtamimab, PRX012) and lower personnel costs, partially offset by restructuring charges.
• Income Tax Provision: A $43.3 million income tax expense was recorded in 2025 compared to a $5.1 million benefit in 2024. This was primarily due to establishing a full valuation allowance against federal deferred tax assets following the restructuring and birtamimab discontinuation.
• Cash Position: Cash and cash equivalents decreased by approximately $140.5 million during the nine-month period, primarily due to operating cash burn.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash of $330.8 million is sufficient to meet obligations for at least the next twelve months. Additional capital will be required for future operations, potentially raised through collaborations (Roche, BMS, Novo Nordisk) or equity/debt financings.
• Program Updates:
  • Prasinezumab: Partner Roche plans to initiate the Phase 3 PARAISO trial for early-stage Parkinson's disease by the end of 2025, following positive Phase 2b PADOVA data.
  • BMS-986446: Received FDA Fast Track designation for Alzheimer's disease; Phase 2 TargetTau-1 trial is ongoing.
  • PRX019: Phase 1 clinical trial initiated in late 2024.
  • Birtamimab: Development discontinued in May 2025 after Phase 3 AFFIRM-AL trial failed to meet endpoints.
• Key Risks:
  • Dependence on third-party collaborators (Roche, BMS, Novo Nordisk) for development and commercialization.
  • Need for additional capital to fund operations beyond the next 12 months.
  • Regulatory and clinical trial risks inherent in drug development.
  • Full valuation allowance on deferred tax assets limits future tax benefits.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $330.8 million cash balance against the projected $170-$178 million full-year 2025 cash burn and future R&D needs.
• Restructuring Completion: Confirm the timeline for the $17.6 million remaining restructuring liability payments, expected by Q4 2025.
• Collaboration Milestones: Monitor progress on Roche's Phase 3 PARAISO trial initiation and BMS's Phase 2 TargetTau-1 trial results, as these drive future milestone revenue.
• Deferred Revenue: Track the recognition of the $2.7 million deferred revenue related to the PRX019 Phase 1 Clinical Trial Obligation.
• Tax Position: Assess the impact of the full valuation allowance on deferred tax assets and the potential for future tax benefits if profitability is achieved.